

**Professor Frederick J. Raal (Derick)**

MBBCh, FRCP, FRCPC, FCP(SA), Cert Endo, MMED, PhD

Director, Carbohydrate & Lipid Metabolism Research Unit

Professor & Head, Division of Endocrinology & Metabolism, University of the Witwatersrand

email: [frederick.raal@wits.ac.za](mailto:frederick.raal@wits.ac.za)

Professor Derick Raal is currently Professor and Head of the Division of Endocrinology and Metabolism, as well as Director of the Carbohydrate and Lipid Metabolism Research Unit, University of the Witwatersrand, Johannesburg, South Africa. After obtaining his MBBCh degree cum laude in 1981 he completed his registrarship in Internal Medicine and obtained his MRCP(UK) and FCP(SA) in 1987, his Master of Medicine in 1991, his FRCP(Canada) in 1995 and the FRCP(UK) in 2000. He sub-specialized in Endocrinology & Metabolism and was awarded his PhD on studies in patients with familial hypercholesterolaemia in June 2000. Professor Raal has received numerous postgraduate awards including the Jack Gear memorial award for medical registrars, the TH Bothwell Research Prize in 2000, the FJ Milne award in 2013 and the University of the Witwatersrand Vice Chancellor's Research Award in 2015. He is a past chairperson and secretary of the Society of Endocrinology, Metabolism and Diabetes of Southern Africa (SEMDSA) and has been the secretary of the Lipid and Atherosclerosis Society of Southern Africa (LASSA) since its inception in 1989.

He has authored or co-authored over 230 original articles and book chapters and has reviewed for several international journals including the New England Journal of Medicine, the Lancet, Circulation, the American Journal of Cardiology, Diabetes Care, Atherosclerosis, and Arteriosclerosis, Thrombosis and Vascular Biology. He is also on the Editorial Board of *Atherosclerosis*. He is a member of several scientific societies including the International Atherosclerosis Society, the European Atherosclerosis Society and the American Heart Association.

Professor Raal is particularly interested in lipids and lipid disorders and has been integrally involved in the management of familial dyslipidaemia, particularly heterozygous and homozygous familial hypercholesterolaemia (FH). His Unit has one of the largest cohorts, if not the largest cohort, of homozygous FH patients in the world and has contributed, and continues to contribute, to the management of these unfortunate patients. The major focus of his research remains the clinical, biochemical, genetic and therapeutic management of this condition and he continues to conduct studies with novel therapies such as PCSK9-inhibitors and anti-sense apo B-100 in this patient group. He is also a keen sportsman and has been awarded provincial colours for both tennis and squash.